Umecrine Cognition presents data showing a reduction of neuroinflammation following treatment with golexanolone
Stockholm, January 10, 2022 – Umecrine Cognition AB today announced nonclinical results showing that its clinical drug candidate golexanolone exerts a normalizing effect on neuroinflammation in the…